Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic
- PMID: 32374026
- PMCID: PMC7267627
- DOI: 10.1111/bjh.16775
Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic
Abstract
This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.
Keywords: ITP; TPO RA; intravenous immunoglobulin; platelets; steroids; thrombosis.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
References
-
- Arabi YM, Mandourah Y, Al‐Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–67. - PubMed
-
- Catala‐Lopez F, Corrales I, Martin‐Serrano G, Tobias A, Calvo G. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta‐analysis of randomized controlled trials. Med Clin. 2012;139:421–9. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
